Alpha-1 Foundation applauds results of RAPID Trial

The RAPID Trial demonstrates the effectiveness of augmentation therapy in slowing emphysema due to Alpha-1 Antitrypsin Deficiency. Results of the trial were announced today at a late-breaking abstract session at the international conference of the American Thoracic Society in Philadelphia. CSL Behring sponsored the trial, which randomly assigned 180 Alpha-1 patients to receive either the augmentation product Zemaira or a placebo for a two-year period.